CFTR and cystic fibrosis: We previously demonstrated that losartan and its anti–TGF-β metabolite EXP3179, which has no angiotensin receptor–blocking properties, could reverse TGF-β1–induced mucociliary dysfunction in an ovine model of CF-like airway disease in vivo and in CF bronchial epithelial (CFBE) cells in the absence of highly effective CFTR modulators in vitro (17).